Shanghai Henlius Biotech has formed a strategic collaboration with Sandoz to develop and commercialize up to 10 monoclonal antibody and antibody-drug conjugate biosimilars globally, excluding China. The partnership builds on their 2025 oncology biosimilars deal and includes upfront and milestone payments totaling up to $322 million, with Henlius expecting invoiced revenue of $100.5 million in 2026. This collaboration leverages Henlius' biologics development and manufacturing capabilities and Sandoz's global commercialization network, aiming to accelerate global market access for these biosimilars. Key products include biosimilars for cetuximab, evolocumab, and belimumab, with most still in early development stages.
Zentek Ltd. has filed a provisional patent for ZEN-EMI-01, a water-based electromagnetic interference (EMI) shielding coating made from purified graphite from its Albany deposit. Unlike traditional metal-based shields that reflect EM energy, this coa...
OS Therapies announced $10 million in debt financing supported by UK VAT refunds and R&D tax credits, providing financial stability into 2027. The company is preparing for key FDA and MHRA meetings in September 2026 to review survival data and finali...
A new 2026 tax rule phases out a bonus deduction for taxpayers aged 65 and older based on modified adjusted gross income (MAGI). Retirees doing Roth IRA conversions to fill tax brackets may unintentionally lose this valuable deduction if their MAGI e...
Solana (SOL) is trading near $75, maintaining support above the crucial $60-$62 zone after a significant decline from its $253 peak. The recent Alpenglow upgrade, which drastically reduces transaction finality times, has been approved by over 98% of ...
A couple sold a long-held property in 2024, generating a large capital gain that raised their reported income for 2024. This higher income triggered increased Medicare premiums for 2026, as Medicare uses tax data from two years prior to set premiums....
